Ad5-nCoV vaccine

Also Known As:

2019-nCoV vaccine Ad5-nCoV; Ad5-nCoV 2019-nCoV vaccine; Ad5-nCoV COVID-19 vaccine; COVID-19 vaccine Ad5-nCoV; Convidicea; Pakvac; Recombinant Novel Coronavirus Vaccine Ad5-nCoV; hAdOx1 nCoV-19; recombinant novel coronavirus vaccine adenoviral vector5

Networked: 5 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Complex Mixtures: 1906
- Biological Products
  - Vaccines: 124365
    - Viral Vaccines: 462
      - COVID-19 Vaccines: 7607
        Ad5-nCoV vaccine: 5

Experts

1.	Almagro, Juan C: 1 article (02/2022)
2.	Cortés-Paniagua, María I: 1 article (02/2022)
3.	Gamboa-Suasnavart, Ramsés: 1 article (02/2022)
4.	González-González, Edith: 1 article (02/2022)
5.	Gómez-Castellano, Keyla M: 1 article (02/2022)
6.	Mendoza-Salazar, Ivette: 1 article (02/2022)
7.	Pérez-Tapia, Sonia M: 1 article (02/2022)
8.	Rodríguez-Luna, Stefany D: 1 article (02/2022)
9.	Santiago-Casas, Giovanni: 1 article (02/2022)
10.	Balcázar-Félix, Paulina: 1 article (09/2021)

Related Diseases

1.	Asymptomatic Infections 01/01/2023 - "Successful clearance of persistent SARS-CoV-2 asymptomatic infection following a single dose of Ad5-nCoV vaccine."
2.	COVID-19 01/01/2023 - "Comparison of antibody persistency through one year between one-dose and two-dose regimens of Ad5-nCoV vaccine for COVID-19." 12/01/2022 - "In individuals without prior COVID-19, the Ad5-nCoV vaccine generated lower NAbs against SARS-CoV-2 than those induced by two doses of the BTN162b2 (Ad5-nCoV 72.10 [55.6-93.4] vs. BTN162b2 98.41 [98.16-98.56], p < 0.0001). " 02/10/2022 - "The patient received a single dose of Ad5-nCoV vaccine (Convidecia™, CanSino Biologics Inc.) one month before developing COVID-19 symptoms. " 12/01/2022 - "In conclusion, the mRNA vaccine (BTN162b2) had a remarkable better ability to produce NAbs and lower reactogenicity than the other platforms, whereas the Ad5-nCov vaccine induced the lowest NAbs response in individuals without a history of COVID-19; therefore, we suggest that a booster could benefit these individuals." 09/20/2021 - "The Ad5-nCoV vaccine induces higher neutralizing antibodies percentage in individuals with prior COVID-19 than those without prior COVID-19 (median [IQR]: 98% [97-98.1] vs. 72% [54-90], respectively; p < 0.0001). "

Related Drugs and Biologics

1.	Neutralizing Antibodies
2.	mRNA Vaccines